Loading patent…
AssigneeCouncil of Scientific and Industrial Research
InventorsSurajit Ghosh, Atanu Biswas, Batakrishna Jana, Saswat Mohapatra, Subhas Chandra Biswas, Suraiya Saleem, Prasenjit Mondal, Anindyasundar Adak, Subhajit Ghosh, Abhijit Saha, Debmalya Bhunia
Estimating the term…
The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with β-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with Aβ peptide in-vitro and shows excellent neuroprotection against Aβ infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.
(canceled)
A nanovesicle having size in the range of 50-600 nm comprising monomeric units of a peptide consisting of the amino acid sequence as set forth in SEQ ID NO:
A method for preventing, for delaying onset or for treatment of Alzheimer's disease in a subject comprising administering a single or multi-dose effective amount of a peptide consisting of the amino acid sequence as set forth in SEQ ID NO:
A peptide consisting of the amino acid sequence as set forth in SEQ ID NO:
Dependencies are inferred from the claim text.